{"id":"emb-01","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Fatigue"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Rash"},{"rate":"5-10%","effect":"Pyrexia"}]},"_chembl":{"chemblId":"CHEMBL4594472","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by binding to PD-1 on T cells, preventing its interaction with PD-L1 on tumor cells and thereby enhancing anti-tumor immune response.","oneSentence":"EMB-01 is an investigational monoclonal antibody targeting PD-1.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:37:09.159Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer, PD-L1 positive"}]},"trialDetails":[{"nctId":"NCT07314294","phase":"PHASE2","title":"Phase II Study of EMB-01 in Recurrent/Metastatic Colorectal Cancer Patients","status":"RECRUITING","sponsor":"Shanghai EpimAb Biotherapeutics Co., Ltd.","startDate":"2025-12-18","conditions":"Metastatic Colorectal Cancer","enrollment":54},{"nctId":"NCT05176665","phase":"PHASE1, PHASE2","title":"EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers","status":"RECRUITING","sponsor":"Shanghai EpimAb Biotherapeutics Co., Ltd.","startDate":"2021-10-21","conditions":"Neoplasms, Neoplasm Metastasis, Metastatic Gastrointestinal Carcinoid Tumor","enrollment":152},{"nctId":"NCT05498389","phase":"PHASE1, PHASE2","title":"EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer","status":"UNKNOWN","sponsor":"Shanghai EpimAb Biotherapeutics Co., Ltd.","startDate":"2023-06","conditions":"Metastatic Lung Non-Small Cell Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8","enrollment":115},{"nctId":"NCT03797391","phase":"PHASE1, PHASE2","title":"A Dose Escalation With Expansion Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors","status":"UNKNOWN","sponsor":"Shanghai EpimAb Biotherapeutics Co., Ltd.","startDate":"2018-12-13","conditions":"Neoplasms, Neoplasm Metastasis, Non-Small-Cell Lung Cancer","enrollment":186},{"nctId":"NCT04868253","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Combination EMB-001 as a Potential Smoking Cessation Treatment","status":"UNKNOWN","sponsor":"Rose Research Center, LLC","startDate":"2021-05-19","conditions":"Smoking Cessation, Tobacco Use Disorder","enrollment":25}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["FIT-013a","metyrapone","oxazepam"],"phase":"phase_2","status":"active","brandName":"EMB-01","genericName":"EMB-01","companyName":"Shanghai EpimAb Biotherapeutics Co., Ltd.","companyId":"shanghai-epimab-biotherapeutics-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"EMB-01 is an investigational monoclonal antibody targeting PD-1. Used for Non-small cell lung cancer, PD-L1 positive.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}